Eikon Therapeutics, Inc.’s Lock-Up Period To Expire on August 4th (NASDAQ:EIKN)

Eikon Therapeutics’ (NASDAQ:EIKN) lock-up period will expire on Tuesday, August 4th. Eikon Therapeutics had issued 21,177,600 shares in its IPO on February 5th. The total size of the offering was $381,196,800 based on an initial share price of $18.00. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on EIKN shares. Weiss Ratings started coverage on shares of Eikon Therapeutics in a research note on Monday, June 1st. They set a “sell (e-)” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen cut Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. Finally, Wedbush lowered their price objective on Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.20.

Eikon Therapeutics Price Performance

EIKN stock opened at $9.21 on Friday. The stock has a fifty day moving average of $10.12. Eikon Therapeutics has a one year low of $7.90 and a one year high of $17.40. The stock has a market capitalization of $498.62 million and a P/E ratio of -3.74.

Eikon Therapeutics (NASDAQ:EIKN) last posted its earnings results on Monday, March 30th. The company reported ($26.23) earnings per share for the quarter.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.